Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

384.85
Delayed Data
As of 1:00pm ET
 -2.69 / -0.69%
Today’s Change
340.09
Today|||52-Week Range
543.55
+4.84%
Year-to-Date
Investors Shun Biotech Stocks
8:32am / TheStreet.com - Paid Partner Content
Biotech Stocks to Watch: Part 1
Nov 20 / TheStreet.com - Paid Partner Content
Orbimed Advisors Llc Buys Clementia Pharmaceuticals Inc, Aetna Inc, Universal Health ...
Nov 20 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close387.54
Today’s open388.40
Day’s range384.25 - 392.99
Volume250,593
Average volume (3 months)782,329
Market cap$41.6B
Dividend yield--
Data as of 1:00pm ET, 11/24/2017

Growth & Valuation

Earnings growth (last year)+39.49%
Earnings growth (this year)+37.60%
Earnings growth (next 5 years)+14.50%
Revenue growth (last year)+18.44%
P/E ratio34.9
Price/Sales8.79
Price/Book9.23

Competitors

 Today’s
change
Today’s
% change
SHPGShire-1.92-1.28%
VRTXVertex Pharmaceutica...-0.49-0.33%
BAXBaxter International...+0.08+0.12%
ALXNAlexion Pharmaceutic...+1.01+0.94%
Data as of 1:01pm ET, 11/24/2017

Financials

Next reporting dateFebruary 13, 2018
EPS forecast (this quarter)$4.45
Annual revenue (last year)$4.9B
Annual profit (last year)$895.5M
Net profit margin18.42%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts